dta Search Results


type linseis mark dta l62  (Linseis Messgerate)
94
Linseis Messgerate type linseis mark dta l62
Type Linseis Mark Dta L62, supplied by Linseis Messgerate, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/DTA+PT+1600/10__4236_slash_msa__2012__33022-83-11-12
Average 94 stars, based on 1 article reviews
type linseis mark dta l62 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
thermogravimetric data  (Linseis Messgerate)
99
Linseis Messgerate thermogravimetric data
Thermogravimetric Data, supplied by Linseis Messgerate, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/STA+L81/10__1002_slash_zaac__202200167-122-0-6
Average 99 stars, based on 1 article reviews
thermogravimetric data - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
linseis tga  (Linseis Messgerate)
96
Linseis Messgerate linseis tga
Linseis Tga, supplied by Linseis Messgerate, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/TGA+L81/10__1088_slash_1757___899x_slash_244_slash_1_slash_012008-45-9-9
Average 96 stars, based on 1 article reviews
linseis tga - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti gitr agonistic antibody  (Bio X Cell)
94
Bio X Cell anti gitr agonistic antibody
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Anti Gitr Agonistic Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/InVivoMAb+anti-mouse+GITR/pm37925106-55-10-15
Average 94 stars, based on 1 article reviews
anti gitr agonistic antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
aav mcherry  (Addgene inc)
93
Addgene inc aav mcherry
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Aav Mcherry, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/pAAV-mCherry-flex-dtA+(Plasmid+%2358536)/pmc06706002-209-17-18
Average 93 stars, based on 1 article reviews
aav mcherry - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
plasmid pet15b lfndta  (Addgene inc)
92
Addgene inc plasmid pet15b lfndta
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Plasmid Pet15b Lfndta, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/pET-15b+LFN-DTA+(Plasmid+%2311075)/pm24671437-45-24-26
Average 92 stars, based on 1 article reviews
plasmid pet15b lfndta - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
pf2 dta  (Addgene inc)
94
Addgene inc pf2 dta
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Pf2 Dta, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/pF2-DTA+(Plasmid+%2342521)/pmc03577784-48-57-78
Average 94 stars, based on 1 article reviews
pf2 dta - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
pb6 rosa26 dta soriano  (Addgene inc)
92
Addgene inc pb6 rosa26 dta soriano
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Pb6 Rosa26 Dta Soriano, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/pB6-ROSA26-DTA-Soriano-for+(Plasmid+%23125745)/bio_rxiv__2023__06__20__545035-113-1-9
Average 92 stars, based on 1 article reviews
pb6 rosa26 dta soriano - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
pf2 dta rosa26  (Addgene inc)
93
Addgene inc pf2 dta rosa26
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Pf2 Dta Rosa26, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/pF2-DTA-Rosa26+(Plasmid+%2342522)/pmc03577784-48-70-78
Average 93 stars, based on 1 article reviews
pf2 dta rosa26 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
primers pjbei 6410 syn open 3  (Addgene inc)
90
Addgene inc primers pjbei 6410 syn open 3
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Primers Pjbei 6410 Syn Open 3, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/pGATOR-DTA+(Plasmid+%2364103)/pm32927940-179-31-26
Average 90 stars, based on 1 article reviews
primers pjbei 6410 syn open 3 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
pl253 plasmid  (Addgene inc)
92
Addgene inc pl253 plasmid
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
Pl253 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/pL253-NEO-DTA+(Plasmid+%2363583)/pmc08389244-34-15-17
Average 92 stars, based on 1 article reviews
pl253 plasmid - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
r26rdta dta  (Jackson Laboratory)
86
Jackson Laboratory r26rdta dta
Fig. 2. Antitumor effects of triple-combination therapy of RT, <t>anti-GITR</t> agonist <t>and</t> <t>PD-L1</t> blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.
R26rdta Dta, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dta/dta+r26rdta/barron_jerika_j__2022__group_2_innate_lymphoid_cells_promote_inhibitory_synapse_development_and_social_behavior-533-72-80
Average 86 stars, based on 1 article reviews
r26rdta dta - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Fig. 2. Antitumor effects of triple-combination therapy of RT, anti-GITR agonist and PD-L1 blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Article Title: Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.

doi: 10.1016/j.radonc.2023.109981

Figure Lengend Snippet: Fig. 2. Antitumor effects of triple-combination therapy of RT, anti-GITR agonist and PD-L1 blockade using an in vivo syngenic murine triple negative breast cancer model. (A) Treatment schedule for mice treated with RT, anti-GITR agonist and PD-L1 blockade. (B) Mean tumor volume of subcutaneous implants at hind limb (left) and flank (right) in mice of each treatment group: Control, agonistic anti-GITR antibody, PD-L1 blockade, RT, agonist anti-GITR antibody + PD-L1 blockade, agonist anti-GITR antibody + RT, PD-L1 blockade + RT and triple-combination therapy. (n = 5 mice per group) (C) The representative samples of lung with metastatic nodules and lung metastasis nodule count by each treatment group. (D) The representative bioluminescence images of subcutaneous nodules before and after each treatment, after subcutaneous injection of 4T1-luc tumor cells. The relative tumor burden of each treatment group is quantified by measuring the luminous intensity of photons emitted from each tumor in the images. (E) Representative images of lung samples with metastatic nodules indicated with an arrow and counts grouped by treatment. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1., PD-L1 blockade.

Article Snippet: The anti-PD-L1 blocking antibody (5 mg/kg; BioXCell, BE0101) and the anti-GITR agonistic antibody (5 mg/kg; BioXCell, BE0063) were intraperitoneally injected on days 10, 12, 14, 17, and on days 11, 13, 15, 17, 19, and 21, respectively.

Techniques: In Vivo, Control, Injection

Fig. 3. Profile of CD8+ cytotoxic T-cells in the tumor microenvironment according to treatment groups. (A) Flow cytometry analysis and immunohistochemistry results for CD8+ cytotoxic T-cells (CD3+ CD8+) (B) in the whole tumor microenvironment, (C) intratumoral region, (D) tumor periphery, and (E) in the stromal region are presented, respectively. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD- L1 blockade.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Article Title: Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.

doi: 10.1016/j.radonc.2023.109981

Figure Lengend Snippet: Fig. 3. Profile of CD8+ cytotoxic T-cells in the tumor microenvironment according to treatment groups. (A) Flow cytometry analysis and immunohistochemistry results for CD8+ cytotoxic T-cells (CD3+ CD8+) (B) in the whole tumor microenvironment, (C) intratumoral region, (D) tumor periphery, and (E) in the stromal region are presented, respectively. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD- L1 blockade.

Article Snippet: The anti-PD-L1 blocking antibody (5 mg/kg; BioXCell, BE0101) and the anti-GITR agonistic antibody (5 mg/kg; BioXCell, BE0063) were intraperitoneally injected on days 10, 12, 14, 17, and on days 11, 13, 15, 17, 19, and 21, respectively.

Techniques: Flow Cytometry, Immunohistochemistry

Fig. 4. Profile of regulatory T-cells (Treg) in the tumor microenvironment according to treatment groups. (A) Flow cytometry analysis and (B) immunohisto chemistry results for Tregs (CD25+ Foxp3+) are presented, respectively. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD-L1 blockade; Treg, regulatory T-cells.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Article Title: Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.

doi: 10.1016/j.radonc.2023.109981

Figure Lengend Snippet: Fig. 4. Profile of regulatory T-cells (Treg) in the tumor microenvironment according to treatment groups. (A) Flow cytometry analysis and (B) immunohisto chemistry results for Tregs (CD25+ Foxp3+) are presented, respectively. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD-L1 blockade; Treg, regulatory T-cells.

Article Snippet: The anti-PD-L1 blocking antibody (5 mg/kg; BioXCell, BE0101) and the anti-GITR agonistic antibody (5 mg/kg; BioXCell, BE0063) were intraperitoneally injected on days 10, 12, 14, 17, and on days 11, 13, 15, 17, 19, and 21, respectively.

Techniques: Flow Cytometry, Immunohistochemistry

Fig. 5. Immune cell profiles in the spleen according to treatment groups analyzed by flow cytometry. (A,B,C) Flow cytometric analysis results for (A) CD8+ cytotoxic T-cells, and (B) Effector memory T-cells (CD44high CD62Llow) and (C) Tregs (CD25+ Foxp3+) of the spleen are presented, respectively. * P < 0.05; ** P < 0.01; *** P<0.001; **** P < 0.0001. RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD-L1 blockade; Treg, regulatory T-cells.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Article Title: Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.

doi: 10.1016/j.radonc.2023.109981

Figure Lengend Snippet: Fig. 5. Immune cell profiles in the spleen according to treatment groups analyzed by flow cytometry. (A,B,C) Flow cytometric analysis results for (A) CD8+ cytotoxic T-cells, and (B) Effector memory T-cells (CD44high CD62Llow) and (C) Tregs (CD25+ Foxp3+) of the spleen are presented, respectively. * P < 0.05; ** P < 0.01; *** P<0.001; **** P < 0.0001. RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD-L1 blockade; Treg, regulatory T-cells.

Article Snippet: The anti-PD-L1 blocking antibody (5 mg/kg; BioXCell, BE0101) and the anti-GITR agonistic antibody (5 mg/kg; BioXCell, BE0063) were intraperitoneally injected on days 10, 12, 14, 17, and on days 11, 13, 15, 17, 19, and 21, respectively.

Techniques: Flow Cytometry

Fig. 6. Production of interferons in plasma. Serum levels of (A) interferon-beta and (B) interferon–gamma at 1 week after administration of RT. * P < 0.05; ** P < 0.01; *** P < 0.001. CON, contrast; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD-L1 blockade.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Article Title: Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.

doi: 10.1016/j.radonc.2023.109981

Figure Lengend Snippet: Fig. 6. Production of interferons in plasma. Serum levels of (A) interferon-beta and (B) interferon–gamma at 1 week after administration of RT. * P < 0.05; ** P < 0.01; *** P < 0.001. CON, contrast; RT, radiation therapy; αGITR, agonist anti-GITR antibody; αPD-L1, PD-L1 blockade.

Article Snippet: The anti-PD-L1 blocking antibody (5 mg/kg; BioXCell, BE0101) and the anti-GITR agonistic antibody (5 mg/kg; BioXCell, BE0063) were intraperitoneally injected on days 10, 12, 14, 17, and on days 11, 13, 15, 17, 19, and 21, respectively.

Techniques: Clinical Proteomics